Iressa (gefitnib), an FDA-approved EGFR inhibitor for lung cancer therapy, causes G1 cell cycle arrest and suppresses invasion by modulating p27 and MMP-2 in OSCC cells 19. Here, EGFR is linked to lung cancer.